PT Dexa Medica (RI)

We are a leading pharmaceutical company in Indonesia, develop, manufacture, and market pharmaceutical products for domestic, regional and global markets.
The purpose of Dexa Medica's Research and Development Department is to develop a variety of pharmaceutical dosage forms to optimize drug's efficacy, safety, and convinient dosing for the customer. We develop various drugs for oral, parenteral, topical and rectal medication. We also develop fixed combination of drugs in special strength designed for Indonesians that have been proven through clinical trials. Furthermore, we have developed what we call distinctive/innovative product, such as capsules containing spherical pellets with sustained and immediate release formulations. We also focus our research activities on drug delivery systems. We conduct new product research and development from laboratory bench to full-production scale based on our commitment to build 'health for all' throughout the nation, the regional, and global. Due to our strong commitment to the health service, solid management, wide network of distribution and excellent commitment to the business ethic, several multinational companies, as well as national companies, have trusted us to established strategic alliances.

Activity:

- Manufacturing
- Research & Development

Product / Technology type(s) covered:

- Drug delivery
- Pharmaceuticals / Therapeutics

Therapeutic targets:

Markets Covered

a. HeadQuarter:

b. Continent(s) active: Asia , Africa

c. Countries active:

Corporate data:

Number of Employees:

Turnover:

Amount:	Year:	Currency:

Year founded:

Partners / Alliances: Strategic alliances: Marketing of Aventis Behring's products in Indonesia. Marketing of Ebewe's products in Indonesia. GlaxoWellcome Indonesia: Co-promotion of 3TC-HBV. Heumann : Marketing of Trunal in Indonesia. Huhtamaki Leiras Oy, Finland: Marketing of Recofol and Dobuject in Indonesia. Novartis Indonesia: Co-promotion of Lescol. Novo Nordisk: Marketing of Novo Nordisk's products in Indonesia. Pfizer Indonesia: Supply agreement of Amlodipin and set-up a joint venture company, Pfidex Pharma. Rhodia: Marketing of Halothane and Isoflurane. SmithKline Beecham Indonesia: Co-marketing of co-amoxyclav.